AstraZeneca Reports real-world evidence Data for Lenacapavir in Hemophilia B

AstraZeneca today announced real-world evidence results for lenacapavir in patients with hemophilia B. The study demonstrated that lenacapavir significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of hemophilia B and support the continued development of lenacapavir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.